The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101.
Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification, the company states in a press release. Biovian has invented a way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing.
“We are pleased to start a collaboration with Remedium Bio and to include Remedium’s AAV candidate in our ongoing second-generation AAV platform development program. Remedium’s therapeutic candidate will be important in the validation of Biovian’s second generation AAV platform – bringing a new level of quality and efficiency to the viral vector manufacturing space,” says Antti Nieminen, CEO at Biovian.
Photo of Antti Nieminen: Biovian